Free to total PSA ratio is not a reliable predictor of prostate biopsy outcome

被引:4
作者
Ciatto, S
Rubeca, T
Confortini, M
Pontenani, G
Lombardi, C
Zendron, P
Di Lollo, S
Crocetti, E
机构
[1] Ctr Studio Prevenz Oncol, I-50131 Florence, Italy
[2] Torre Galli Hosp, Dept Urol, Florence, Italy
[3] Univ Florence, Inst Pathol, Florence, Italy
关键词
diagnosis; prostate cancer; prostate specific antigen;
D O I
10.1177/030089160409000311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims and background: The aim of this study was to assess the validity of predictors of prostate biopsy outcome in order to improve their positive predictive value. Material and methods: The study material consisted of a consecutive series of 410 prostate biopsies performed during 2003. The variables tested as possible predictors were age, findings at palpation (DRE) and ultrasonography (TRUS), total prostate-specific antigen (PSA), and free-to-total prostate-specific antigen (F/T) ratio. The association with biopsy outcome (cancer vs non-cancer) was investigated by univariate and multivariate analysis. Results: All tested variables showed a statistically signifi-cant and independent association with biopsy outcome both in univariate and multivariate analysis. Nevertheless, no variable had good performance as a biopsy indicator: depending on the considered variable, three to nine cancer biopsies would be delayed in order to avoid ten benign biopsies. Using 0.12, 0.15 and 0.20 as the cutoff for F/T would avoid 77.3%, 64.4% and 43.1% of benign biopsies but would delay 54.0%, 35.6% and 21.0% of cancer biopsies, respectively. Conclusion: Although it may contribute to diagnostic suspicion, F/T should never exclude a biopsy indicated because of suspicion arising from other diagnostic tests.
引用
收藏
页码:324 / 327
页数:4
相关论文
共 17 条
[1]   THE USE OF PROSTATE SPECIFIC ANTIGEN DENSITY TO ENHANCE THE PREDICTIVE VALUE OF INTERMEDIATE LEVELS OF SERUM PROSTATE SPECIFIC ANTIGEN [J].
BENSON, MC ;
WHANG, IS ;
OLSSON, CA ;
MCMAHON, DJ ;
COONER, WH .
JOURNAL OF UROLOGY, 1992, 147 (03) :817-821
[2]   LONGITUDINAL EVALUATION OF PROSTATE-SPECIFIC ANTIGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE DISEASE [J].
CARTER, HB ;
PEARSON, JD ;
METTER, J ;
BRANT, LJ ;
CHAN, DW ;
ANDRES, R ;
FOZARD, JL ;
WALSH, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (16) :2215-2220
[3]  
CATALONA WJ, 1995, JAMA-J AM MED ASSOC, V274, P1214
[4]  
Ciatto S, 2002, Radiol Med, V103, P219
[5]   Analysis of PSA velocity in 1666 healthy subjects undergoing total PSA determination at two consecutive screening rounds [J].
Ciatto, S ;
Bonardi, R ;
Lombardi, C ;
Zappa, A ;
Gervasi, G ;
Cappelli, G .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2002, 17 (02) :79-83
[6]   Reliability of volume or age-adjusted prostate specific antigen to improve diagnostic accuracy [J].
Ciatto, S ;
Bonardi, R ;
Mazzotta, A ;
Santoni, R .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1995, 10 (04) :226-228
[7]   Predicting prostate biopsy outcome by findings at digital rectal examination, transrectal ultrasonography, PSA, PSA density and free-to-total PSA ratio in a population-based screening setting [J].
Ciatto, S ;
Bonardi, R ;
Lombardi, C ;
Cappelli, G ;
Castagnoli, A ;
D'Agata, A ;
Zappa, M ;
Gervasi, G .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2001, 16 (03) :179-182
[8]   Large-scale randomized prostate cancer screening trials:: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial [J].
de Koning, HJ ;
Auvinen, A ;
Sanchez, AB ;
da Silva, FC ;
Ciatto, S ;
Denis, L ;
Gohagan, JK ;
Hakama, M ;
Hugosson, J ;
Kranse, R ;
Nelen, V ;
Prorok, PC ;
Schröder, FH .
INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (02) :237-244
[9]   Lead times and overdetection due to prostate-specific antigen screening:: Estimates from the European randomized study of screening for prostate cancer [J].
Draisma, G ;
Boer, R ;
Otto, SJ ;
van der Cruijsen, IW ;
Damhuis, RAM ;
Schröder, FH ;
de Koning, HJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (12) :868-878
[10]   Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate [J].
Eskew, LA ;
Bare, RL ;
McCullough, DL .
JOURNAL OF UROLOGY, 1997, 157 (01) :199-202